Amgen agrees to buy Otezla rights for $13.4 bn: Bristol-Myers Squibb
Amgen has agreed to acquire the global rights to Otezla, a drug used for the treatment of psoriasis and psoriatic arthritis, for $13.4 billion in cash, Bristol Myers Squibb said Monday.
Aug 26, 2019
0
2